Prescription drugs are expensive because of a combination of factors that compound on each other: the cost of developing new drugs, patent systems that block competition for years, a rebate structure that actually pushes list prices higher, and profit margins nearly double those of other large companies. No single villain explains the problem. It’s a system where every layer adds cost, and patients end up absorbing more of it than they should.
Development Costs Are High, but Not the Whole Story
Bringing a new drug to market is genuinely expensive. After accounting for the cost of all the failed candidates that never make it through clinical trials, plus the capital tied up during years of development, the estimated cost per successful drug is around $879 million. That figure comes from a U.S. Department of Health and Human Services analysis, and it’s actually lower than what the pharmaceutical industry itself typically claims.
The process takes 10 to 15 years on average. A company might test thousands of compounds, run multi-phase clinical trials involving tens of thousands of patients, and still see most candidates fail before approval. Those failures aren’t free. Their costs get folded into the price of the drugs that do succeed. This is a real expense, and it does justify some of the pricing gap between brand-name drugs and, say, consumer products. But it doesn’t explain everything, especially when you look at what happens after a drug reaches the market.
Patents and Exclusivity Block Competition
Once a drug is approved, the manufacturer typically holds patents and regulatory exclusivities that prevent competitors from selling cheaper versions. This is by design: without some period of protected pricing, companies would have little incentive to invest in risky development. The problem is how aggressively that protection gets extended.
Pharmaceutical companies routinely use a strategy called “evergreening,” where they make minor modifications to an existing drug to obtain new patents. That might mean switching from a capsule to a tablet, changing from an immediate-release to a sustained-release formula, or tweaking inactive binding agents. None of these changes represent meaningful innovation for patients, but each one can reset the clock on competition. Companies can also stack more than a dozen different types of regulatory exclusivities on top of their patents, creating what researchers describe as walls of protection: some extend the length of time before a competitor can enter the market, others make it harder for a competitor to break through even when the time is up.
The result is that many brand-name drugs face no generic competition for far longer than their original patent would suggest. And without competition, there’s no downward pressure on price.
What Happens When Generics Finally Arrive
Generic competition does work, when it’s allowed to happen. Data from Medicare claims between 2007 and 2022 shows a clear pattern: prices drop about 20% once roughly three generic competitors enter the market. With 10 or more competitors, prices fall 70% to 80% below the pre-generic price within three years of the first generic entry.
The catch is that many expensive drugs, particularly newer biologics, face very few competitors. And for drugs still under patent protection, there are zero. The entire pricing structure depends on this bottleneck. A drug with no competition can essentially charge whatever the market will bear, and in healthcare, patients often have no choice but to bear it.
The Rebate System Inflates Prices
Between drug manufacturers and the patients who take their medications sits a layer of middlemen called pharmacy benefit managers (PBMs). These companies negotiate rebates from manufacturers on behalf of insurers. In theory, this should lower costs. In practice, it often does the opposite.
Research from USC’s Schaeffer Center found that for every $1 increase in rebates paid to PBMs, the drug’s list price rises by $1.17. Manufacturers raise their sticker prices to fund the rebates, and then some. The rebate dollars flow to PBMs and insurers, but the inflated list price is what uninsured patients pay at the pharmacy counter. Even insured patients get hurt: if your plan requires coinsurance (a percentage of the drug’s cost) or you haven’t met your deductible, your out-of-pocket payment is calculated from that inflated list price, not the lower post-rebate price your insurer actually pays.
This creates a perverse cycle where higher rebates lead to higher list prices, which lead to higher out-of-pocket costs for the patients who can least afford them.
Pharmaceutical Profit Margins Exceed Most Industries
Drug companies are significantly more profitable than the average large public company. A study published in JAMA, covering data from 2000 through 2018, found that major pharmaceutical companies had a median net profit margin of 13.8%, compared to 7.7% for S&P 500 companies overall. That’s nearly double.
The gap is even more striking higher up the income statement. Pharmaceutical companies posted a median gross profit margin of 76.5%, meaning that for every dollar of revenue, about 77 cents remained after covering the direct cost of making the product. The S&P 500 median was 37.4%. This reflects both the low manufacturing cost of most pills and the premium pricing that patent protection allows.
There’s a common perception that drug companies spend more on marketing than on research. That was true decades ago: in 1979, the industry spent 33% more on advertising than on R&D. But the ratio has flipped. By 2018, R&D spending reached $61.1 billion while advertising was $9 billion, about 15% of the R&D budget. As a share of sales, marketing expenses dropped from 6% to under 3%, while R&D climbed from under 5% to 19%. The industry does spend heavily on promotion, but the bigger driver of high prices is market exclusivity and the pricing power it grants.
Biologics Cost More to Make and Sell
Not all drugs are created equal in terms of manufacturing. Traditional small-molecule drugs (the kind you swallow as a pill) cost roughly $5 per pack to produce. Biologics, the large, complex proteins used to treat conditions like rheumatoid arthritis, cancer, and autoimmune diseases, cost about $60 per pack to manufacture. That’s a 12-fold difference at the production level.
Biologics require living cell cultures, precise temperature control, and extensive quality testing that chemical synthesis doesn’t demand. They also can’t be copied as easily as traditional generics. “Biosimilars,” the biologic equivalent of generics, must go through more extensive testing to prove they work like the original, which means fewer competitors and slower price reductions. Many of the most expensive drugs patients encounter today, the ones costing thousands or tens of thousands of dollars per dose, are biologics.
Orphan Drugs and Small Patient Populations
Drugs for rare diseases face a unique pricing dynamic. The Orphan Drug Act gives manufacturers strong incentives to develop treatments for conditions affecting small numbers of patients: tax credits for clinical trials, exemption from regulatory fees, and seven years of market exclusivity after approval. These incentives exist because without them, it wouldn’t be financially viable to develop drugs for a few thousand patients.
But with a small customer base and guaranteed exclusivity, manufacturers set prices extremely high to recoup their investment. Annual treatment costs for orphan drugs routinely reach six figures. The same protections that make these drugs possible also make them some of the most expensive medications on the market.
Limited Government Price Controls
The U.S. has historically been an outlier among wealthy nations in not allowing its largest drug purchaser, Medicare, to negotiate prices directly with manufacturers. That changed partially with the Inflation Reduction Act, which authorized Medicare to negotiate prices on a small number of high-cost drugs for the first time. The first round selected 10 medications, including widely used blood thinners, diabetes drugs, and treatments for heart failure and arthritis. Negotiated prices for these drugs take effect in 2026.
Ten drugs is a start, but Medicare covers thousands. In most other high-income countries, government agencies negotiate or set drug prices across the board, which is a major reason the same medications cost far less in Canada, Europe, or Australia. In the U.S., manufacturers have largely been free to set their own prices for the commercially insured and uninsured populations, constrained only by what PBMs and private insurers will agree to in rebate negotiations.
The result of all these overlapping factors is a system where each piece, development costs, patent extensions, the rebate structure, limited negotiation, manufacturing complexity, and protected profit margins, pushes prices upward. Fixing any single piece helps at the margins, but the reason drugs are so expensive isn’t one thing. It’s all of them at once.